MONORES ® - Clenbuterol
MONORES ® is a drug based on Clenbuterol hydrochloride
THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive respiratory tract syndromes.
Indications MONORES ® - Clenbuterol
MONORES ® is indicated in the treatment of bronchial asthma and chronic obstructive bronchopathy characterized by an asthmatic component.
Mechanism of action MONORES ® - Clenbuterol
MONORES ® is a specialty based on Clenbuterol, an active ingredient listed among the selective agonists of Beta 2 adrenergic receptors.
At the opening of the other sympathomimetic amines with selectivity towards the aforementioned receptors, Clenbuterol also binds with high affinity the Beta 2 adrenergic receptors expressed by the tracheobronchial smooth muscle, determining a sensitive bronchodilation important in restoring the correct patency of the respiratory tract.
The contextual fluidifying action on nasal mucus secretions makes the mucus significantly more fluid, thus facilitating its elimination through ciliary mucus clearance, and further improving the patient's ventilatory capacity.
Following administration of MONORES ®, the absorbed portion of Clenbuterol is subsequently eliminated via the kidney.
Studies carried out and clinical efficacy
IMMUNOLOGICAL EFFECTS OF CLENBUTEROL
J Pharmacol Sci. 2007 Jun; 104: 146-52. Epub 2007 Jun 8.
Beta2-agonist clenbuterol induced changes in the distribution of white blood cells in rats.
Shirato K, Tanihata J, Motohashi N, Tachiyashiki K, Tomoda A, Imaizumi K.
Experimental study that tests the immunological effects related to the use of Clenbuterol, demonstrating how this drug can cause a redistribution of white blood cells by increasing the number of neutrophils and monocytes at the expense of eosinophils and lymphocytes.
CLENBUTEROL IN THE TREATMENT OF OBSTRUCTIVE PATHOLOGIES OF THE AIRWAYS
Zhonghua Yi Xue Za Zhi (Taipei). 1991 Jan; 47: 13-7.
Spiropent (clenbuterol): another choice for patients with chronic reversible airways obstruction.
On WJ, Perng RP.
This work demonstrates how the use of Clenbuterol can represent a valid choice, both in terms of therapeutic efficacy and costs, for the long-term treatment of obstructive airway diseases, even reversible ones.
OVERDOSE OF CLENBUTEROL AND HEART DISEASE
J Med Toxicol. 2007 Jun; 3: 56-60.
Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation.
Daubert GP, Mabasa VH, Leung VW, Aaron C.
Study that demonstrates how the abuse of Clenbuterol, especially outside of medical prescriptions and beyond the dosages normally indicated, could be responsible, with a certain frequency of tachycardia and atrial fibrillation, sometimes with a severe and inauspicious outcome.
Method of use and dosage
Clenbuterol 10-20 mcg tablet;
Syrup of 0.1 - 0.4 mg of Clenbuterol per 100 ml of product.
The definition of the therapeutic scheme is up to the doctor after carefully evaluating the patient's general state of health and the severity of his clinical picture.
Dosages, timing of intake and pharmaceutical format therefore vary considerably from patient to patient on the basis of relative needs.
Generally in adults with asthma or asthmatic bronchopathies, the maximum recommended dose is that of 20 mcg twice a day, taking care, however, to identify in the maintenance phase the minimum dosage necessary to guarantee the therapeutic effect.
MONORES ® warnings - Clenbuterol
MONORES ® therapy must be defined and supervised by a physician specialized in the treatment of respiratory diseases.
Given the biological activity of Clenbuterol, the use of this drug should take place with particular caution in patients suffering from cardiovascular diseases, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, potentially more susceptible to the side effects of therapy.
The need to increase the doses of the drug, to maintain the same therapeutic effect, could indicate an aggravation of the clinical conditions of the disease, such as to require further medical supervision and the possible need to modify the current therapy.
MONORES ® contains lactose among its excipients, therefore it is not indicated in patients with galactose intolerance, lactase enzyme deficiency and glucose-galactose malabsorption syndrome.
The use of MONORES ®, outside the medical prescriptions for which it is indicated, is prohibited in and out of the competition.
It is recommended to store the drug out of the reach of children.
PREGNANCY AND BREASTFEEDING
The use of MONORES ® during pregnancy could be justified by unavoidable clinical needs and should in any case be under the careful supervision of your doctor.
However, it would be important to consider, before its use during pregnancy and in the subsequent breastfeeding period, the ability of Clenbuterol to inhibit uterine contractions and to concentrate in pharmacologically active doses in breast milk.
The patient receiving MONORES ® should avoid the simultaneous intake of beta 2 agonist drugs and non-selective beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalaemia.
Contraindications MONORES ® - Clenbuterol
The use of MONORES ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with severe heart disease, glaucoma, prostatic hypertrophy and urinary retention or intestinal obstruction syndrome:
Undesirable Effects - Side Effects
MONORES ® therapy may expose the patient to the risk of hyperglycemia, hypokalaemia, nervousness and restlessness, dizziness, headache and tremor, myalgia, muscle spasm, arrhythmia, palpitations, tachycardia and paradoxical bronchospasm.
The onset of symptoms linked to hypersensitivity to the active ingredient has also rarely been documented.
MONORES ® is a drug subject to mandatory medical prescription.
The information on MONORES ® - Clenbuterol published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.